drugset / Trial / NCT00616564
Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma
Phase 2
Completed
36 enrolled
Mt. Sinai Medical Center, Miami
Bayer · collabChiron Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
High-dose IL-2 treatment for metastatic melanoma has been approved by the FDA in 1998. Studies of GM-CSF plus IL-2 have not addressed the approved dose and schedule. This protocol will study the combination of HD-IL2 and GM-CSF given the potential synergistic interactions discussed above.
Timeline
- Start
- 2006-02
- Primary completion
- 2009-09
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sargramostim | Protein / enzyme biologic | — | — |